Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase показать больше
1 clinical trials in select solid tumors and myeloid malignancies and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6 and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6 and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
– моментальные уведомления о рынке акций
